When and under what circumstances can a patent owner obtain an injunction against imminent infringement or, as expressed in the Patents Act, preparatory acts of infringement? This question is of particular interest for pharmaceutical patents during the regulatory process relating to authorisations of generic medicinal products.
Jonas Westerberg and Ludvig Holm at Lindahl comment on this subject in the latest newsletter from ILO.